MARSHALL WACE, LLP

Position in VCEL — Vericel Corp

CIK 1318757 LONDON, X0

Position in VCEL

as of Jun 30, 2026 · filed Aug 13, 2026 Compact

Position Value

$3,505,634

-$3,142,907 QoQ

Shares Held

78,796

-61.9% QoQ

Ownership

0.154%

of shares outstanding

% of Portfolio

0.00%

of 13F equity value

Holder Rank

#80

of 317 holders

Holding Since

Mar 2020

13 quarters on record

Voting authority Sole 0% Shared 100% None 0%

Healthcare · as of Jun 30, 2026

MARSHALL WACE, LLP holds $3,055,517,440 across 267 Biotechnology names. VCEL ranks #114 (0.1% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	VRTX	Vertex Pharmaceuticals Inc / Ma	543,897	$270,169,956
2	INCY	Incyte Corp	1,310,154	$148,519,056
3	RPRX	Royalty Pharma plc	2,450,669	$137,409,009
4	SYRE	Spyre Therapeutics, Inc.	991,693	$88,042,503
5	ALNY	Alnylam Pharmaceuticals, Inc.	259,799	$78,207,292
6	TVTX	Travere Therapeutics, Inc.	1,333,207	$75,739,488
7	MANE	Veradermics, Inc	585,560	$71,988,746
8	DFTX	Definium Therapeutics, Inc.	1,298,946	$61,102,419

13 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-06-30	$3,505,634	78,796	-61.9%	Shares	Other	2026-08-13
2026-03-31	$6,648,541	206,669	+126.6%	Shares	Other	2026-05-15
2025-12-31	$3,284,687	91,216	+580.4%	Shares	Other	2026-02-13
2024-03-31	$697,380	13,406	-51.2%	Shares	Other	2024-05-15
2023-06-30	$1,032,987	27,495	-87.2%	Shares	Other	2023-08-14
2023-03-31	$6,314,384	215,361	-13.6%	Shares	Other	2023-05-15
2022-09-30	$5,784,154	249,317	+109.8%	Shares	Other	2022-11-14
2022-06-30	$2,992,189	118,832	-18.4%	Shares	Other	2022-08-15
2022-03-31	$5,562,844	145,548	+4702.0%	Shares	Other	2022-05-16
2021-12-31	$119,118	3,031	-98.9%	Shares	Other	2022-02-14
2020-09-30	$5,307,547	286,430	-35.1%	Shares	Sole	2020-11-16
2020-06-30	$6,103,520	441,644	-36.5%	Shares	Sole	2020-08-13
2020-03-31	$6,378,321	695,564	—	Shares	Sole	2020-05-15
No filing history on record for this holder in this stock.